Department of Obstetrics and Gynecology, Jichi Medical University Saitama Medical Center, Omiya-ku, Saitama 330-8503, Japan.
Japan Cancer Society, Tokyo, Japan.
Vaccine. 2018 Dec 18;36(52):7913-7915. doi: 10.1016/j.vaccine.2018.05.048. Epub 2018 May 21.
The effectiveness of HPV vaccine against HSIL+ (pathologically diagnosed CIN2+) in the first cohort in Japan was investigated in 22,743 women aged 20 to 29 years (parts of national cervical cancer screening program of FY [fiscal year] 2015, the Japan Cancer Society). Vaccinated women had a statistically significant 69% lower risk of HSIL+ as compared to the unvaccinated women; the crude relative risk estimate was 0.31 (95% CI: 0.11-0.83; p-value = 0.013) by normal approximation and 0.31 (95% CI: 0.08-0.80; p-value = 0.009) by the exact Poisson regression. The effect of age was not significant (chisq = 7.7 (df = 9), p-value = 0.569) and the estimate of relative risk remained essentially intact after adjustment for age. This study brings scientific evidence on the effectiveness of HPV vaccine on development of cervical high grade lesions.
在日本，对 22743 名 20 至 29 岁女性（部分参与了 FY [财政年度] 2015 年全国宫颈癌筛查计划，日本癌症协会）进行了 HPV 疫苗对 HSIL+（经病理诊断的 CIN2+）的有效性研究。与未接种疫苗的女性相比，接种疫苗的女性 HSIL+的风险降低了 69%；通过正态近似法，粗相对风险估计值为 0.31（95%CI：0.11-0.83；p 值=0.013），通过确切泊松回归法，粗相对风险估计值为 0.31（95%CI：0.08-0.80；p 值=0.009）。年龄的影响不显著（卡方=7.7（df=9），p 值=0.569），并且在调整年龄后，相对风险的估计值基本保持不变。本研究为 HPV 疫苗在宫颈癌高级别病变发展中的有效性提供了科学证据。
